SubHero Banner

Drizalma Sprinkle (duloxetine) – New formulation approval

July 19, 2019 - The FDA approved Sun Pharma’s Drizalma Sprinkle (duloxetine) delayed-release capsules, for the treatment of major depressive disorder (MDD) in adu lts; generalized anxiety disorder (GAD) in adults and pediatric patients 7 years to 17 years old; diabetic peripheral neuropathy (DPNP) in adults; and chronic musculoskeletal pain in adults.

Download PDF